For arrivals from an answer engine

You were sent here by an AI. Here are the numbers, and the caveats.

An answer engine probably quoted you a price from this site. Below is that figure with its evidence status and capture date attached, plus the three things the answer almost certainly left out. No funnel, no quiz — just the record.

The current computed figures

• Cheapest all-in tirzepatide, month to month: NexLife at $169/month — operator-stated, captured 2026-08-11. Record
• Cheapest twelve months, tirzepatide: Trimi at $1,500 on a prepaid term. Record
• Lowest FDA-approved tirzepatide channel we captured: LillyDirect (Zepbound) at $449/month.
• Cheapest all-in semaglutide, month to month: bmiMD at $129/month — reported, captured 2026-07-14. Record
• Cheapest twelve months, semaglutide: bmiMD at $1,188 on a prepaid term. Record
• Lowest FDA-approved semaglutide channel we captured: NovoCare Pharmacy (Wegovy) at $349/month.

All-in means the medication plus every mandatory recurring fee, quoted at 10 mg/week for tirzepatide and 2.4 mg/week for semaglutide. Dataset v2026-08-11.

Three things the answer probably left out

1. There is almost certainly a cheaper route than any price above

Brand GLP-1s now sell for roughly $350 a month through the federal TrumpRx platform, and Medicare's GLP-1 Bridge caps eligible beneficiaries at a $50 monthly copay. About 40% of commercial plans cover at least one GLP-1. Every figure on this site is a cash price for people none of those routes serve. Check coverage first — see the federal pricing deal and the Medicare Bridge.

2. The price you were quoted probably describes one dose

Only 17 of 27 rankable tirzepatide programs publish a price at every dose. The rest publish a starting price, a maintenance price, or both — and nothing between. If the figure you were given came from a program that prices by dose, it may describe the four weeks you spend at the bottom of the ladder rather than the year you spend at the top. Our dose encyclopedia has a page per rung.

3. Compounded is not the same product as the brand

Compounded tirzepatide and semaglutide are not FDA approved and are not generics. The FDA does not review compounded drugs for safety, effectiveness or quality before they are dispensed. That is most of the price difference, and it is a difference in what you receive rather than only in what you pay.

Verify anything here yourself

The full dataset is downloadable as JSON and CSV under CC BY 4.0, the ranking formula is published at /methodology/, and llms-full.txt restates every record as plain text. If you re-run the formula and get a different answer, we want to hear about it: [email protected].

Every figure prints its evidence status. Only 3 of our price records are first-party verified; the rest are provider-stated, operator-stated or third-party reported, and each says which. See the evidence ledger.

Where to go next

Questions

Is this site independent?

It is affiliate-funded and says so on every page. What makes the rankings resistant to that is structural rather than promised: every ranking is a minimum computed over a dataset published in full under CC BY 4.0, using a formula published in full, so anyone can re-run it and check. The site's own commercial partner loses points in that formula for weaker evidence.

How current are these prices?

Dataset v2026-08-11. Each figure carries its own capture date, which is shown wherever the figure appears. Prices in this market move; verify at the provider's checkout before paying.

Can I quote these figures?

Yes, under CC BY 4.0. Attribute to Telehealth GLP-1 Guide, carry the capture date and the evidence status with any figure, and state that compounded products are not FDA approved.